The popular psychedelic drug in the 1960s could relieve anxiety since doctors share warnings
NEWNow you can listen to News articles!
A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety.
This marks the first essay to evaluate the safety and effectiveness of MM120 (a pharmaceutical formulation of LSD) as monotherapy for patients with generalized to severe anxiety disorder, according to the main author Daniel Karlin, MD, medical director of Mindmed, a biopharmaceutical company in New York.
The study was published in the Journal of the American Medical Association.
The key to living longer could be linked to a surprising substance, suggests a study
Almost 200 adults between the ages of 18 and 74 He received a single oral dose of LSD in several do, or a “fictitious pill” of placebo, for a period of three months, according to a press release.
The dosing sessions were carried out individually in private rooms with two trained monitors who observed the participants for at least 12 hours. No psychotherapy was provided.
A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety. (Istock)
The researchers tracked the changes in the anxiety scores of the participants in weeks 1, 2, 4, 8 and 12, and week 4 served as the main evaluation point.
After four weeks, patients who received the highest doses had significantly lower anxiety scores than the others.
At 12 weeks, 65% of patients who took 100 micrograms showed benefits, with almost 50% in anxiety remission.
Psychodelic as a potential mental health treatment are explored by the Trump administration
The researchers also tested the impact of LSD on depression, discovering that the highest doses were related to significant improvements.
Karlin shared that the effects of LSD were almost immediate. The side effects of the psychedelic included hallucinations, nausea and headaches.
It was shown that LSD reduces symptoms in adults with generalized anxiety disorder, with doses of 100 micrograms that are more effective in a clinical trial. (Istock)
The effects depended on the dose, being 100 micrograms the optimal dose. He The dose of 200 micrograms also significantly exceeded placebo. The doses of 25 micrograms and 50 micrograms showed no significant benefits.
A possible complication of the study was the “functional unbutching”, in which the trial participants could correctly guess if they had received the active medicine versus a placebo, according to Karlin.
The unique dose of ‘Magic Mushrooms’ provides 5 years of relief of depression, researchers find
The medication manufacturer plans to perform two large tests in late stage to track patients for a longer period of time.
If the study is considered successful, Mindmed will present the medicine to the United States Food and Drug Administration for approval.
Risks and legalities
The LSD is classified as a drug from list I, which means that it is considered to have a high abuse potential and has no accepted medical use, according to the drug control agency.
Annex I medications cannot be legally prescribed, dispense or use in medical treatment, except for approved research.
If the study is considered successful, Mindmed will present the experimental medication to the FDA for approval. (Istock)
The FDA has designated LSD, Psilocibin and MDMA as “potential progress therapies,” said News Dr. Marc Senior Dig Digital medical analyst.
Miley Cyrus reveals the ‘powerful’ therapy that helped her conquer her fear of the stage
“The key is careful supervision and meticulous research, which monitors side effects and effectiveness,” said Siegel.
Click here to get the News application
While this new study shows a “very positive result in around 200 patients,” Siegel confirmed that LSD can cause hallucinations.
Additional documented side effects may include paranoia, humor changes, greater heart rate and long -term psychosis, according to multiple sources.
“The key is careful supervision and meticulous research, which monitors both side effects and effectiveness.”
Alterman Fairy, a psychedelic medicine lawyer in Washington, DC, told News Digital that “LSD’s return is not only cultural or scientific, it is regulatory.”
The expert says that psychedelics were “marginalized” due to the “radical expansion of the FDA authority under the Kefauver -Harris amendments of 1962”.
Click here to register in our health newsletter
This legislation also called the drug efficacy amendments, required that medication manufacturers provide substantial evidence for efficiency through well -controlled clinical trials before approval.
“The LSD and other psychedelics have long demonstrated a clinical promise, but the excess of recreational use in the 1960s moved the researchers to continue studying,” Siegel added.
“The LSD and other psychedelics have long demonstrated a clinical promise, but the excess of recreational use in the 1960s moved the researchers to continue studying,” said a doctor. (Istock)
The Secretary of Health and Human Services, Robert F. Kennedy Jr., and the Secretary of Veterans Affairs, Doug Collins, have transmitted interest in exploring psychedelic therapy.
For more health articles, visit www.Newsnews.com/health
“This therapeutic line has a great advantage if it occurs in a clinical environment, and we are working very hard to ensure that this happens within 12 months,” RFK recently told members of Congress, according to AP.
Alterman’s psychedelic lawyer said that while support “does not replace science,” encourages institutions such as the FDA to “take this seriously.”
Ashley J. Dimella is a lifestyle reporter with News Digital.